18F-FDG PET/CT imaging in oncology

Ann Saudi Med. Jan-Feb 2011;31(1):3-13. doi: 10.4103/0256-4947.75771.


Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of management is changed. This review provides guidance for oncologists/radiotherapists and clinical and surgical specialists on the use of 18F-FDG PET/CT in oncology.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18
  • Humans
  • Neoplasm Staging
  • Neoplasms / diagnostic imaging*
  • Positron-Emission Tomography / methods*
  • Tomography, X-Ray Computed / methods*


  • Fluorodeoxyglucose F18